Compare Merck & Co., Inc. (MRK) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Merck & Co., Inc. trades at $133.12 (market cap $321.77B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.7. The key difference: Merck & Co., Inc. pays a 2.61% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MRK | QDTY | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $131.84 | $46.71 |
52-Week Low | $77.60 | $36.57 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
QDTY trades at $39.61, down 0.48% with neutral technical signals. The stock shows consistent weekly dividend distributions averaging $0.26-0.30 per share throughout 2026. Technical indicators suggest a balanced market with RSI at neutral levels and bearish moving average signals. Support and resistance cluster around $39-40, indicating tight trading range consolidation.
The outlook remains balanced with dividend income providing stability, though limited fundamental data availability warrants caution. Key risks include market volatility and dependency on ETF distribution strategies. The stock's performance hinges on broader market trends and YieldMax's distribution management effectiveness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
